Earnings Call Summary | Talphera(TLPH.US) Q1 2024 Earnings Conference
Earnings Call Summary | Talphera(TLPH.US) Q1 2024 Earnings Conference
The following is a summary of the Talphera, Inc. (TLPH) Q1 2024 Earnings Call Transcript:
以下是塔爾費拉公司（TLPH）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Talphera reported no revenues for Q1 2024, with cash operating expenses totaling $3.9 million, marking a decrease from $4.8 million the previous year.
The company is forecasting full-year 2024 cash operating expenses to be between $21 million to $23 million.
As of the end of the first quarter, the company had cash and investments totaling $18.6 million.
Separate financings yielded $14 million in total - $8 million from DSUVIA royalties and milestones and $6 million from equity financing with Nantahala and Rosalind.
塔爾費拉報告稱，2024年第一季度沒有收入，現金運營支出總額爲390萬美元，較上年的480萬美元有所下降。
該公司預計，2024年全年現金運營支出將在2100萬美元至2300萬美元之間。
截至第一季度末，該公司的現金和投資總額爲1,860萬美元。
單獨的融資總額爲1400萬美元，其中800萬美元來自DSUVIA的特許權使用費和里程碑，600萬美元來自與Nantahala和Rosalind的股權融資。
Business Progress:
業務進展：
Talphera closed agreements with five major academic institutions and is continuing with clinical trial agreements for five more potential NEPHRO CRRT study sites.
Patient enrollment for the study is set to begin this quarter, and the company forecasts a fast completion rate.
Challenges in patient enrollment have caused some timeline delays, but rapid enrollment and quick study completion are expected to mitigate further setbacks.
Progress continues on the manufacturing and related activities for Niyad, with a commercial launch anticipated in 2025.
Estimated total sales for Niyad across CRRT and intermittent hemodialysis are expected to exceed $200 million.
Talphera has closed two financing deals worth $18 million specifically for Niyad's development and is engaging in partnerships to ensure its success.
Dr. Shakil Aslam is appointed as the new Chief Development Officer, effective May 20, 2024.
Talphera已與五個主要學術機構達成協議，並將繼續就另外五個潛在的NEPHRO CRRT研究地點簽訂臨床試驗協議。
該研究的患者入組定於本季度開始，該公司預計完成率很快。
患者入組方面的挑戰導致了一些時間表延遲，但快速入組和快速完成研究有望緩解進一步的挫折。
Niyad的製造和相關活動繼續取得進展，預計將於2025年商業上市。
預計Niyad在CRRT和間歇性血液透析方面的總銷售額將超過2億美元。
Talphera已經完成了兩筆價值1800萬美元的融資協議，專門用於Niyad的發展，並正在建立合作伙伴關係以確保其成功。
沙基爾·阿斯拉姆博士被任命爲新任首席開發官，自2024年5月20日起生效。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。